Molecular stress brought on by diabetes, fatty liver disease and other chronic conditions can all cause proteins to put on the brakes. Instead of zipping around the cell and bumping into each other to ...

A University of Liverpool study links Alzheimer’s disease to disrupted mechanical signaling between proteins APP and talin in ...

A new study indicates that the loss of brain volume associated with the Alzheimer's drug lecanemab shows the drug is working ...

Behold the Body. Electron microgram of a Biondi body shows a dense core surrounded by filaments that bind gold-labeled secondary antibody to TMEM239 (black dots). [Courtesy of Ghetti et al., 2024.] ...

Tau behaves abnormally in the brain in people with Alzheimer’s disease. This latest study points to a reason why.

In mice, inhibiting protein S-palmitoylation Counteracted accumulation of harmful proteins in neurons and delayed onset and progression of cognitive decline.

Brain volume loss linked to new Alzheimer’s immunotherapies, such as lecanemab, is caused by the removal of amyloid plaques rather than neuronal damage.

A future treatment for Alzheimer disease may involve a nasal spray. Researchers at Università Cattolica and Fondazione Policlinico Universitario A. Gemelli IRCCS have discovered that by inhibiting the ...

Alzheimer’s disease is a long, slow neurodegenerative calamity, and scientists are still hunting for blood biomarkers that reflect all its specific stages. At the Clinical Trials on Alzheimer’s ...

A loss of brain volume associated with new immunotherapies for Alzheimer's disease may be caused by the removal of amyloid ...

Similarly, there were no significant effects on Alzheimer’s fluid biomarkers favoring AL002, and amyloid PET imaging demonstrated no ... candidates aimed at a broad and diverse range of protein and ...

MR technologist reviews icometrix AI report on the Philips BlueSeal MRI console icometrix' FDA-cleared quantitative brain ...